华东医药

000963.SZ

Wind Industry: 医疗保健 > 医疗设备与服务 > 医疗保健提供商与服务 > 保健护理产品经销商

公司创建于1993年，总部位于浙江杭州，于1999年12月在深圳证券交易所上市。历经30余年的发展，公司业务覆盖医药全产业链，拥有医药工业、医药商业、医美、工业微生物四大业务板块，已发展成为集医药研发、生产、经销为一体的大型综合性医药上市公司。公司医药工业深耕于专科、慢病用药及特殊用药领域的研发、生产和销售，已形成完备的医药生产制造和质量研究体系，并形成以慢性肾病、移植免疫、内分泌、消化系统等领域为主的核心产品管线，拥有多个在国内具有市场优势的一线临床用药，同时通过自主开发、外部引进、项目合作等方式重点在内分泌、自身免疫和肿瘤三大核心治疗领域的创新药及高技术壁垒仿制药进行研发布局，并已经形成每年有创新药陆续上市的良好节奏。公司医药商业拥有中西药、医疗器械、药材参茸、健康产业四大业务板块。公司医美业务秉承“全球化运营布局，双循环经营发展”战略，以国际化视野，通过前瞻性布局，打造了综合化、差异化的产品矩阵，产品数量和覆盖领域均居行业前列。公司在工业微生物领域已深耕40余年，有着深厚的产业基础和产业转化能力，成功开发和制造了多种微生物药物，构筑了微生物产品研发和生产的关键技术体系，现有微生物发酵产品规模和技术水平均处于业内领先水平。

ESG Score Industry Ranking:
5 / 118 (医疗保健提供商与服务)

ESG Rating Distribution(医疗保健提供商与服务)

AAA

2.54%

17.80%

23.73%

BBB

31.36%

17.80%

1.69%

CCC

Trend of Rating

About Wind ESG Rating

Wind has developed a rigorous rating methodology based on the core connotations of ESG, aligning with international standards and frameworks, and incorporating the characteristics of Chinese companies, to assess the company's essential ESG performance, risk and its ability to operate sustainably.

Focusing on the ESG risks and opportunities of each industry, the companies are rated on a AAA-CCC scale relative to the performance of their industry peers. Wind ESG rating is updated annually or in response to major changes.

The Wind ESG Rating Issuer Communication Platform (esg.wind.com.cn) is now available. Rated companies can access their detailed rating information through this platform, and communicate with or provide feedback to the Wind ESG Rating team regarding specific rating components. For any additional questions, please feel free to send an email to GR.ESG@wind.com.cn.

ESG Score

ESG Score：7.94Updated on 2026-10-29

07.9410

Management & Practices Score：4.94Updated on 2026-09-18

04.947

Controversies Score：3.00Updated on 2026-10-29

03.003

ESG Score Comparison

Indicator	Company Score	Industry Average	Weight
Environmental	5.39	3.34	5.17%
Social	7.03	3.84	67.23%
Governance	7.45	5.25	27.59%

Wind ESG Rating Framework

Building on the foundation of domestic and international ESG policies and standards, our proprietary ESG rating framework considers the development of Chinese capital market and integrates the characteristics of the Chinese companies in various industries. The Wind ESG Rating framework is composed of management & practice and controversies assessment, including:

500+ management & practices indicators, covering E, S and G pillars, reflecting long-term ESG fundamental impacts
1,200+ risk labels, covering news, regulatory penalties and lawsuits, reflecting impact of short-term risks

Management & practice score is the weighted summation of E, S and G pillar scores. The weights reflect both the relative impact of each issue within each industry and the negative or positive contribution of each industry to the environment and society relative to other industries.

Controversies score and ESG score are updated daily, E, S and G pillar scores and management & practice score are updated with underlying data, corresponding data are released on various channels, including Wind Financial Terminal.

Explore More

Wind ESG Rating Methodology.pdf1,198KB Wind ESG Ratings FAQs.pdf755KB

More Details

Peer Comparison(118 companies in the industry) ?

Ranking	Code	Security Name	ESG Rating	ESG Score	Controversies Score	Management & Practices Score	Environmental	Social	Governance
1	300143.SZ	盈康生命	AA	8.89	3.00	5.89	7.09	8.82	7.68
2	2325.HK	云康集团	AA	8.19	2.99	5.19	5.36	7.87	6.73
3	300015.SZ	爱尔眼科	AA	8.17	2.99	5.18	6.28	7.34	7.75
4	9860.HK	艾迪康控股	A	7.97	3.00	4.97	3.99	7.26	7.29
5	000963.SZ	华东医药	A	7.94	3.00	4.94	5.39	7.03	7.45
6	000950.SZ	重药控股	A	7.84	2.99	4.85	5.54	7.03	6.95
7	603882.SH	金域医学	A	7.83	2.94	4.89	4.05	7.26	6.89
8	301103.SZ	何氏眼科	A	7.82	2.98	4.84	4.10	7.35	6.40
9	600056.SH	中国医药	A	7.63	2.99	4.63	4.83	6.45	7.38
10	2666.HK	环球医疗	A	7.61	3.00	4.61	3.78	6.81	6.57